Showing results (311-320 of 1,189) with videos related to

Sort By:
Pageof 119
BMC Pharmacology & Toxicology|April 14, 2025
Sevoflurane reduces cardiomyocyte injury in a hypoxia/reoxygenation model of cardiomyocytes through the linc01278/miR-134-5pt regulatory axisLing Wang, Changhua Zhu, Yangge Shao, et al.
BMC Pharmacology & Toxicology|April 1, 2025
Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS dataJiakuan Tu, Chaoxiang Zhang, Yichun Qiu, et al.
BMC Pharmacology & Toxicology|April 17, 2025
Identification of key therapeutic targets in nicotine-induced intracranial aneurysm through integrated bioinformatics and machine learning approachesQiang Ma, Longnian Zhou, Zhongde Li
BMC Pharmacology & Toxicology|April 21, 2025
A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)Xiaomei Xiong, Xiuwen Zhang, Fengmin Tang, et al.
BMC Pharmacology & Toxicology|April 16, 2025
Trimetazidine effect on kidney function in patients undergoing coronary proceduresYasser Abdel-Hady, Mohammed Taha, Ahmed El Barbary, et al.
BMC Pharmacology & Toxicology|April 19, 2025
Coenzyme Q10 microemulsion ion-activated gel: a promising ophthalmic delivery system for enhanced corneal protection and sustained releaseShao-Hua Dong, Yue Gao, Yue Li, et al.
BMC Pharmacology & Toxicology|May 7, 2025
Effect of CYP3A4 inhibitor and induction on the pharmacokinetics and safety of FHND9041, a novel EGFR T790M inhibitor, in healthy ChineseChang Lu, Dongmei Cheng, Yunqiu Xie, et al.
BMC Pharmacology & Toxicology|May 19, 2025
Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitisMin Wu, Qianqian Li, Min Fang, et al.
BMC Pharmacology & Toxicology|May 13, 2025
Identifying Lactylation-related biomarkers and therapeutic drugs in ulcerative colitis: insights from machine learning and molecular dockingYao Yang, Xu Sun, Bin Liu, et al.
BMC Pharmacology & Toxicology|May 12, 2025
Melatonin enhances everolimus efficacy in breast cancer by suppressing mTOR pathway activation and promoting apoptosis and mitochondrial functionŞeyma Demirkesen, Yakup İriağaç, Erdoğan Selçuk Şeber, et al.
Pageof 119